Scott Charles Johnson, | |
9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 | |
(414) 805-0805 | |
Not Available |
Full Name | Scott Charles Johnson |
---|---|
Gender | Male |
Speciality | Urology |
Experience | 14 Years |
Location | 9200 W Wisconsin Ave, Milwaukee, Wisconsin |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1912223553 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208800000X | Urology | 036.137435 (Illinois) | Secondary |
208800000X | Urology | 56567 (Wisconsin) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Froedtert Memorial Lutheran Hospital | Milwaukee, WI | Hospital |
Community Memorial Hospital | Menomonee falls, WI | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
The Medical College Of Wisconsin Inc | 2668384371 | 1813 |
Froedtert Andthe Medical College Of Wisconsin Community Physicians Inc | 3678760063 | 1040 |
News Archive
Eli Lilly and Company announced Phase I data on LY2127399, a human monoclonal antibody that neutralizes B-cell activating factor (BAFF), for use in combination with bortezomib in patients with previously-treated multiple myeloma.
Scientists at Mount Sinai School of Medicine have discovered a subpopulation of cells that display cancer stem cell properties and resistance to chemotherapy, and participate in tumor progression. This breakthrough could lead to the development of new tests for early cancer diagnosis, prognostic tests, and innovative therapeutic strategies, as reported in Cancer Cell.
EraGen Biosciences, a rapidly growing molecular diagnostics company and Bayer HealthCare LLC, Diagnostics Division, announced today that EraGen has licensed its patented MultiCode-PLx® System to Bayer HealthCare in an exclusive worldwide agreement for Cystic Fibrosis.
Frontotemporal dementia (FTD) is a progressive neurodegenerative brain disorder, which affects the frontal and temporal lobes. Unlike other types of dementia, it more commonly occurs in individuals in their 50s and 60s, and is therefore referred to as a "younger-onset dementia".
› Verified 1 days ago
Entity Name | The Medical College Of Wisconsin Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1699720086 PECOS PAC ID: 2668384371 Enrollment ID: O20031120000259 |
News Archive
Eli Lilly and Company announced Phase I data on LY2127399, a human monoclonal antibody that neutralizes B-cell activating factor (BAFF), for use in combination with bortezomib in patients with previously-treated multiple myeloma.
Scientists at Mount Sinai School of Medicine have discovered a subpopulation of cells that display cancer stem cell properties and resistance to chemotherapy, and participate in tumor progression. This breakthrough could lead to the development of new tests for early cancer diagnosis, prognostic tests, and innovative therapeutic strategies, as reported in Cancer Cell.
EraGen Biosciences, a rapidly growing molecular diagnostics company and Bayer HealthCare LLC, Diagnostics Division, announced today that EraGen has licensed its patented MultiCode-PLx® System to Bayer HealthCare in an exclusive worldwide agreement for Cystic Fibrosis.
Frontotemporal dementia (FTD) is a progressive neurodegenerative brain disorder, which affects the frontal and temporal lobes. Unlike other types of dementia, it more commonly occurs in individuals in their 50s and 60s, and is therefore referred to as a "younger-onset dementia".
› Verified 1 days ago
Entity Name | Froedtert &the Medical College Of Wisconsin Community Physicians Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1568787448 PECOS PAC ID: 3678760063 Enrollment ID: O20101210000699 |
News Archive
Eli Lilly and Company announced Phase I data on LY2127399, a human monoclonal antibody that neutralizes B-cell activating factor (BAFF), for use in combination with bortezomib in patients with previously-treated multiple myeloma.
Scientists at Mount Sinai School of Medicine have discovered a subpopulation of cells that display cancer stem cell properties and resistance to chemotherapy, and participate in tumor progression. This breakthrough could lead to the development of new tests for early cancer diagnosis, prognostic tests, and innovative therapeutic strategies, as reported in Cancer Cell.
EraGen Biosciences, a rapidly growing molecular diagnostics company and Bayer HealthCare LLC, Diagnostics Division, announced today that EraGen has licensed its patented MultiCode-PLx® System to Bayer HealthCare in an exclusive worldwide agreement for Cystic Fibrosis.
Frontotemporal dementia (FTD) is a progressive neurodegenerative brain disorder, which affects the frontal and temporal lobes. Unlike other types of dementia, it more commonly occurs in individuals in their 50s and 60s, and is therefore referred to as a "younger-onset dementia".
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Scott Charles Johnson, 9200 W Wisconsin Avenue, Milwaukee, WI 53226-3522 Ph: (414) 805-0805 | Scott Charles Johnson, 9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 Ph: (414) 805-0805 |
News Archive
Eli Lilly and Company announced Phase I data on LY2127399, a human monoclonal antibody that neutralizes B-cell activating factor (BAFF), for use in combination with bortezomib in patients with previously-treated multiple myeloma.
Scientists at Mount Sinai School of Medicine have discovered a subpopulation of cells that display cancer stem cell properties and resistance to chemotherapy, and participate in tumor progression. This breakthrough could lead to the development of new tests for early cancer diagnosis, prognostic tests, and innovative therapeutic strategies, as reported in Cancer Cell.
EraGen Biosciences, a rapidly growing molecular diagnostics company and Bayer HealthCare LLC, Diagnostics Division, announced today that EraGen has licensed its patented MultiCode-PLx® System to Bayer HealthCare in an exclusive worldwide agreement for Cystic Fibrosis.
Frontotemporal dementia (FTD) is a progressive neurodegenerative brain disorder, which affects the frontal and temporal lobes. Unlike other types of dementia, it more commonly occurs in individuals in their 50s and 60s, and is therefore referred to as a "younger-onset dementia".
› Verified 1 days ago
Mark Ehlers, Urology Medicare: Medicare Enrolled Practice Location: 2801 W Kinnickinnic River Pkwy Ste 330, Milwaukee, WI 53215 Phone: 414-649-1280 Fax: 414-649-1288 | |
Dr. Michael L Guralnick, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Department Of Urology, Milwaukee, WI 53226 Phone: 414-805-0805 Fax: 414-805-0771 | |
Dr. Arman Cicic, D.O. Urology Medicare: Accepting Medicare Assignments Practice Location: 2600 N Mayfair Rd Ste 580, Milwaukee, WI 53226 Phone: 414-476-0430 | |
Dr. Pedro M. Banda, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2311 N Prospect Ave, Milwaukee, WI 53211 Phone: 414-319-3000 Fax: 414-319-3087 | |
Dr. Jay I Sandlow, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Dept Of Urology, Milwaukee, WI 53226 Phone: 414-805-0805 Fax: 414-805-0771 | |
Joshua Alan Bodie, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Department Of Urology, Milwaukee, WI 53226 Phone: 414-805-0805 Fax: 414-805-0771 | |
Mr. Michael Ernst Mitchell, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 9000 W Wisconsin Ave, Milwaukee, WI 53226 Phone: 414-805-3666 |